BRPI0603053A - previsão de reicidiva de osso de cáncer de mama - Google Patents

previsão de reicidiva de osso de cáncer de mama

Info

Publication number
BRPI0603053A
BRPI0603053A BRPI0603053-0A BRPI0603053A BRPI0603053A BR PI0603053 A BRPI0603053 A BR PI0603053A BR PI0603053 A BRPI0603053 A BR PI0603053A BR PI0603053 A BRPI0603053 A BR PI0603053A
Authority
BR
Brazil
Prior art keywords
breast cancer
prediction
cancer bone
bone recurrence
recurrence
Prior art date
Application number
BRPI0603053-0A
Other languages
English (en)
Inventor
Yixin Wang
Yi Zhang
David Atkins
Anieta M Sieuwerts
Marcel Smid
Jan G M Klijin
John W M Martens
John A Foekens
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BRPI0603053A publication Critical patent/BRPI0603053A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Zoology (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Signal Processing (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

"PREVISãO DE REICIDIVA DE OSSO DE CáNCER DE MAMA". A presente invenção refere-se a um método de provisão de previsão de recidiva de câncer de mama em osso que é realizado através de análise da expressão de um grupo de genes. Perfis de expressão de gene em uma variedade de meios tal como microdisposições estão incluídos assim como kits que os contêm.
BRPI0603053-0A 2005-08-02 2006-08-02 previsão de reicidiva de osso de cáncer de mama BRPI0603053A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70474005P 2005-08-02 2005-08-02

Publications (1)

Publication Number Publication Date
BRPI0603053A true BRPI0603053A (pt) 2007-03-20

Family

ID=37398743

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0603053-0A BRPI0603053A (pt) 2005-08-02 2006-08-02 previsão de reicidiva de osso de cáncer de mama

Country Status (10)

Country Link
US (1) US20070031873A1 (pt)
EP (1) EP1754795A1 (pt)
JP (1) JP2007049991A (pt)
CN (1) CN1995388A (pt)
AR (1) AR055594A1 (pt)
AU (1) AU2006203169A1 (pt)
BR (1) BRPI0603053A (pt)
CA (1) CA2553665A1 (pt)
IL (1) IL177006A0 (pt)
NZ (1) NZ548655A (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290073A3 (en) * 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
WO2008036776A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20090131348A1 (en) * 2006-09-19 2009-05-21 Emmanuel Labourier Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008073915A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
AU2007333107A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
AU2007333109A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro RNAs
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
EP2162459B1 (en) * 2007-05-01 2017-10-04 University of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
EP2260110B1 (en) * 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
WO2009111643A2 (en) * 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
WO2010124372A1 (en) 2009-04-29 2010-11-04 Genomedx Biosciences, Inc. Systems and methods for expression-based classification of thyroid tissue
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US20120142544A1 (en) 2009-06-02 2012-06-07 University Of Miami Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US10734115B1 (en) 2012-08-09 2020-08-04 Cerner Innovation, Inc Clinical decision support for sepsis
US10431336B1 (en) 2010-10-01 2019-10-01 Cerner Innovation, Inc. Computerized systems and methods for facilitating clinical decision making
US11398310B1 (en) 2010-10-01 2022-07-26 Cerner Innovation, Inc. Clinical decision support for sepsis
US20120089421A1 (en) 2010-10-08 2012-04-12 Cerner Innovation, Inc. Multi-site clinical decision support for sepsis
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10628553B1 (en) 2010-12-30 2020-04-21 Cerner Innovation, Inc. Health information transformation system
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US8856156B1 (en) 2011-10-07 2014-10-07 Cerner Innovation, Inc. Ontology mapper
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US10249385B1 (en) 2012-05-01 2019-04-02 Cerner Innovation, Inc. System and method for record linkage
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
US10946311B1 (en) 2013-02-07 2021-03-16 Cerner Innovation, Inc. Discovering context-specific serial health trajectories
US10769241B1 (en) 2013-02-07 2020-09-08 Cerner Innovation, Inc. Discovering context-specific complexity and utilization sequences
US11894117B1 (en) 2013-02-07 2024-02-06 Cerner Innovation, Inc. Discovering context-specific complexity and utilization sequences
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US20160143594A1 (en) * 2013-06-20 2016-05-26 University Of Virginia Patent Foundation Multidimensional time series entrainment system, method and computer readable medium
US10854334B1 (en) 2013-08-12 2020-12-01 Cerner Innovation, Inc. Enhanced natural language processing
US10483003B1 (en) 2013-08-12 2019-11-19 Cerner Innovation, Inc. Dynamically determining risk of clinical condition
US12020814B1 (en) 2013-08-12 2024-06-25 Cerner Innovation, Inc. User interface for clinical decision support
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
WO2017192562A1 (en) * 2016-05-02 2017-11-09 University Of Virginia Patent Foundation Method, system, and computer readable medium for generating pulse oximetry predictive scores (pops) for adverse preterm infants
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
CN108977547B (zh) * 2018-08-14 2019-05-28 江门市中心医院 Tspan1在乳腺癌转移的诊断、预后及治疗中的应用
CN110423816B (zh) * 2018-10-12 2023-06-27 天津医科大学肿瘤医院 乳腺癌预后量化评估系统及应用
SG11202106130UA (en) * 2018-12-08 2021-07-29 Pfs Genomics Inc Transcriptomic profiling for prognosis of breast cancer
KR20220056847A (ko) * 2019-06-21 2022-05-06 커날 바이오로직스, 인크. 조작된 종양선택적 단백질 발현
KR102204958B1 (ko) 2019-10-28 2021-01-20 삼성에스디에스 주식회사 의료 검사 결과 데이터의 처리 방법
US11730420B2 (en) 2019-12-17 2023-08-22 Cerner Innovation, Inc. Maternal-fetal sepsis indicator
WO2023034955A1 (en) * 2021-09-02 2023-03-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Machine learning-based systems and methods for predicting liver cancer recurrence in liver transplant patients
CN115350187B (zh) * 2022-08-30 2023-08-29 中山大学 异丙托溴铵在抑制肺癌骨转移中的应用
CN116064663A (zh) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 利用rps基因促进载体稳定表达的方法及其功能基因

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136182A (en) 1996-06-07 2000-10-24 Immunivest Corporation Magnetic devices and sample chambers for examination and manipulation of cells
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
AU3035699A (en) * 1998-03-27 1999-10-18 Seibel, Markus Determination of the probability of bone metastases in patients with primary carcinomas
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
ATE386804T1 (de) * 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7363165B2 (en) 2000-05-04 2008-04-22 The Board Of Trustees Of The Leland Stanford Junior University Significance analysis of microarrays
WO2001098543A2 (en) * 2000-06-21 2001-12-27 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003016471A2 (en) * 2001-08-13 2003-02-27 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
US20030194734A1 (en) 2002-03-29 2003-10-16 Tim Jatkoe Selection of markers
JP2005537790A (ja) * 2002-09-05 2005-12-15 ガーバン インスティテュート オブ メディカル リサーチ 新規診断および治療方法およびそのための試薬類
US7425414B2 (en) * 2004-02-06 2008-09-16 Health Research, Inc. Method of prognosis of metastasis by detection of FRA12E fragile site within the SMRT gene/locus at chromosome 12q24
ES2504242T3 (es) 2004-02-20 2014-10-08 Janssen Diagnostics, Llc Pronóstico de cáncer de mama
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development

Also Published As

Publication number Publication date
CN1995388A (zh) 2007-07-11
AU2006203169A1 (en) 2007-02-22
JP2007049991A (ja) 2007-03-01
EP1754795A1 (en) 2007-02-21
AR055594A1 (es) 2007-08-29
CA2553665A1 (en) 2007-02-02
NZ548655A (en) 2009-01-31
US20070031873A1 (en) 2007-02-08
IL177006A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
BRPI0603053A (pt) previsão de reicidiva de osso de cáncer de mama
BRPI0518734A2 (pt) prognàstico de cÂncer de pulmço
BRPI0403169A (pt) Prognósticos de câncer colorretal
BR112013007441A2 (pt) produção de alfa-olefinas usando sintases de policetídeo
BR112014028801A2 (pt) ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco
IN2012DN02485A (pt)
IN2009DN05722A (pt)
CL2011003129A1 (es) Procedimiento para determinar riesgo de padecer enfermedad cardiovascular que comprende determinar la presencia de polimorfismos de un solo nucleotido (snp)
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
GB201315760D0 (en) Methods and compositions of molecular profiling for disease diagnostics
EA200970519A1 (ru) Полиморфы сукцината 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2h-пиримидин-1-илметил]-4-фторбензонитрил и способы их применения
EA201400984A2 (ru) Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
BR112015014987A2 (pt) Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
BRPI0705106A (pt) composições de toner
BRPI0403290A (pt) Prognósticos para câncer de mama
MX2010005960A (es) Biomarcadores de braf.
BR112012026536A2 (pt) sistemas e métodos para predizer deficiência gastrointestinal
WO2010120143A3 (ko) 간암 예후 마커
EP2374884A3 (en) Human miRNAs isolated from mesenchymal stem cells
MX2013004747A (es) Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson.
WO2005083429A8 (en) Breast cancer prognostics
WO2009153774A3 (en) Compositions and methods for prognosis of ovarian cancer
SG142186A1 (en) Breast tumour grading

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]